Efficacy of gonadotropin-releasing hormone agonist addition for luteal phase support in women with repeated implantation failure undergoing intracytoplasmic sperm injection cycles
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
GnRH agonist administration in the luteal phase has been suggested to beneficially affect the outcome of intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) cycles. This blind randomized controlled study evaluates the effect of GnRH (Gonadotropine Releasing Hormone) agonist administration on ICSI outcome in GnRH antagonist ovarian stimulation protocol in women with 2 or more previous IVF/ICSI-ET failures.
Methods
One hundred IVF failure women who underwent ICSI cycles and stimulated with GnRH antagonist ovarian stimulation protocol, were included in the study. Women were randomly assigned to intervention (received a single dose injection of GnRH agonist (0.1 mg of Decapeptil) subcutaneously 6 days after oocyte retrieval) and control (did not receive GnRH agonist) groups. Implantation and clinical pregnancy rates were the primary outcome measures.
Results
Although the age of women, the number of embryos transferred in the current cycle and the quality of the transferred embryos were similar in the two groups, there was a significantly higher rate of implantation (Mann Whitney test, p = 0.041) and pregnancy (32.6% vs. 12.5%, p = 0.030, OR = 3.3, 95%CI, 1.08 to 10.4) in the intervention group.
Conclusion
Our results suggested that, in addition to routine luteal phase support using progesterone, administration of 0.1 mg of Decapeptil 6 days after oocyte retrieval in women with previous history of 2 or more IVF/ICSI failures led to a significant improvement in implantation and pregnancy rates after ICSI following ovarian stimulation with GnRH antagonist protocol.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 42 years（—）
- 性别
- Female
入选标准
- •Inclusion: couples with two or more IVF Failure with good quality embryo transfer; women with antagonist cycle; women with at least one embryo for transfer; women under IVF wiht ones gamet and women under 42 years.
- •Exclusion criteria: cycles with preimplantation genetic diagnosis; women with anatomical uterine disorders or hydrosalpinx and women with thyroid disorders.
排除标准
- 未提供